Statement from Sarah Yim, M.D., acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA ’s Center for Drug Evaluation and Research, on FDA’s continued progress facilitating competition in the biologic marketplace with approval of 25th biosimilar product
FDA has taken another step to further foster biologics competition with the approval of 25th biosimilar, Abrilada (adalimumab - afzb), a biosimilar to Humira. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 15, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis
Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritis INDIANAPOLIS, Nov. 12, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today the 52-w... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, psoriatic arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 12, 2019 Category: Pharmaceuticals Source Type: news

China's Bio-Thera Gets Approval for Humira Biosimilar China's Bio-Thera Gets Approval for Humira Biosimilar
China ' s Bio-Thera Solutions Ltd has won a regulatory approval for its version of AbbVie Inc ' s blockbuster rheumatoid arthritis treatment Humira (adalimumab), paving the way for the first such biosimilar to enter the world ' s second-largest drug market.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 9, 2019 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

China's Bio-Thera gets approval for Humira biosimilar
China's Bio-Thera Solutions Ltd has won a regulatory approval for its version of AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world's second-largest drug market. (Source: Reuters: Health)
Source: Reuters: Health - November 7, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis Arthritis Drug Falls Short in Challenge to Global Bestseller Novartis Arthritis Drug Falls Short in Challenge to Global Bestseller
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx (secukinumab) can beat the world ' s best-selling drug Humira (adalimumab) in treating a type of arthritis.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - November 5, 2019 Category: Orthopaedics Tags: Rheumatology News Source Type: news

Novartis Cosentyx ® shows encouraging results versus Humira® from first-of-its-kind head-to-head trial in psoriatic arthritis
Novartis, a leader in rheumatology and immuno-dermatology, announced results from the EXCEED head-to-head trial comparing Cosentyx® (secukinumab) to Humira®* (adalimumab) in patients with active psoriatic arthritis (PsA)[1]. While Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, it showed numerically higher results versus Humira®*[1]. (Source: World Pharma News)
Source: World Pharma News - November 4, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Novartis arthritis drug " narrowly misses " against Humira
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug, Cosentyx, can beat the world ' s best-selling drug Humira in treating arthritis. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 1, 2019 Category: Pharmaceuticals Source Type: news

Risk for Birth Defects Not Increased With Adalimumab
FRIDAY, Nov. 1, 2019 -- Adalimumab exposure in pregnancy does not increase the risk for birth defects, according to a study published online Oct. 18 in PLOS ONE. Christina D. Chambers, from the University of California San Diego in La Jolla, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 1, 2019 Category: Pharmaceuticals Source Type: news

Novartis arthritis drug falls short in challenge to global bestseller
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx can beat the world's best-selling drug Humira in treating a type of arthritis. (Source: Reuters: Health)
Source: Reuters: Health - November 1, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Therapeutic IBD Drug Concentrations May Vary With Different Assays Therapeutic IBD Drug Concentrations May Vary With Different Assays
In patients with inflammatory bowel disease (IBD), concentrations of infliximab and adalimumab varied depending on whether they were assessed with the Enzyme-Linked Immunosorbent Assay (ELISA) or the Homogeneous Mobility Shift Assay (HMSA), researchers found.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 22, 2019 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Study Suggests Adalimumab Exposure in Pregnancy Does Not Increase...
602 Pregnancies Examined by the Non-Profit Organization of Teratology Information Specialists(PRWeb October 18, 2019)Read the full story at https://www.prweb.com/releases/study_suggests_adalimumab_exposure_in_pregnancy_does_not_increase_birth_defects_risk/prweb16660500.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 18, 2019 Category: Pharmaceuticals Source Type: news

Humira, Rituxan Top List of U.S. Drugs With Biggest Price Increases -report Humira, Rituxan Top List of U.S. Drugs With Biggest Price Increases -report
Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 10, 2019 Category: Infectious Diseases Tags: Public Health & Prevention News Source Type: news

Humira, Rituxan top list of U.S. drugs with biggest price increases: report
AbbVie Inc's rheumatoid arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed. (Source: Reuters: Health)
Source: Reuters: Health - October 8, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Cyltezo (Adalimumab-ADBM Injection, for Subcutaneous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 26, 2019 Category: Drugs & Pharmacology Source Type: news

Vedolizumab Beats Adalimumab for Ulcerative Colitis Remissions
WEDNESDAY, Sept. 25, 2019 -- In moderate-to-severe ulcerative colitis, vedolizumab is superior to adalimumab for achieving clinical remission and endoscopic improvement, but not corticosteroid-free clinical remission, and ustekinumab is superior to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 25, 2019 Category: Pharmaceuticals Source Type: news